Market Report Focused on Dyslipidemia-Pipeline Review, H2 2016
Dyslipidemia-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Dyslipidemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.
Complete report available @ Dyslipidemia-Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
- The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects
- The report assesses Dyslipidemia therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dyslipidemia
- The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects
- The report assesses Dyslipidemia therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dyslipidemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acasti Pharma Inc. AFFiRiS AG Akcea Therapeutics Inc Allergan Plc Alnylam Pharmaceuticals, Inc. Amgen Inc. Arisaph Pharmaceuticals, Inc. AstraZeneca Plc BASF SE BCWorld Pharm Co. Ltd. BioRestorative Therapies, Inc. Cadila Pharmaceuticals Limited Cardax, Inc. Catabasis Pharmaceuticals, Inc. Cerenis Therapeutics Holding SA Chong Kun Dang Pharmaceutical Corp. CJ HealthCare Corp. Connexios Life Sciences Pvt. Ltd. CymaBay Therapeutics, Inc. Daewoong Pharmaceutical Co., Ltd. Daiichi Sankyo Company, Limited Debiopharm International SA Eli Lilly and Company Esperion Therapeutics, Inc. Gemphire Therapeutics Inc. GlaxoSmithKline Plc Golden Biotechnology Corp. HanAll Biopharma Co., Ltd. Hanmi Pharmaceuticals, Co. Ltd. Huons Co., Ltd. Hyundai Pharmaceutical Co., Ltd. Innovent Biologics, Inc. IPCA Laboratories Limited Jeil Pharmaceutical Co., Ltd. Jenrin Discovery, Inc. JW Pharmaceutical Corporation Kissei Pharmaceutical Co., Ltd. Kotobuki Pharmaceutical Co., Ltd. Kowa Company, Ltd. Kymab Limited Kyorin Pharmaceutical Co., Ltd. LG Life Science LTD. Lipicard Technologies Limited Lipigon Pharmaceuticals AB LipimetiX Development Inc Lotus Pharmaceutical Co., Ltd. Matinas BioPharma Holdings, Inc. Merck & Co., Inc. Nimbus Therapeutics, LLC Nippon Chemiphar Co., Ltd. Omeros Corporation Pfizer Inc. Pharmena SA Protalix BioTherapeutics, Inc. Regeneron Pharmaceuticals Inc Sancilio & Company, Inc. Takeda Pharmaceutical Company Limited Thetis Pharmaceuticals LLC Torrent Pharmaceuticals Limited Yuhan Corporation Zydus Cadila Healthcare Limited
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:55
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home